Research Paper Volume 14, Issue 19 pp 7941—7958
ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer
Figure 3. Evaluation and validation of Lasso-Cox regression model for pancreatic cancer. (A) Risk-based Kaplan-Meier survival curve for 68 pancreatic cancer patients treated with gemcitabine. (B) Risk-value Kaplan-Meier survival curve for 113 pancreatic cancer patients with no medication information. (C) AUC area of pancreatic cancer patients in the model group at 1, 3 and 5 years. (D) AUC area of pancreatic cancer patients in the validation group at 1, 3 and 5 years.